Cargando…
Omadacycline for the Treatment of Mycobacterium abscessus Disease: A Case Series
BACKGROUND: Omadacycline is an aminomethylcycline antimicrobial approved by the US Food and Drug Administration in 2018 for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections. It has in vitro activity against nontuberculous mycobacteria, including Mycobacte...
Autores principales: | Pearson, Jeffrey C, Dionne, Brandon, Richterman, Aaron, Vidal, Samuel J, Weiss, Zoe, Velásquez, Gustavo E, Marty, Francisco M, Sax, Paul E, Yawetz, Sigal |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7566545/ https://www.ncbi.nlm.nih.gov/pubmed/33094118 http://dx.doi.org/10.1093/ofid/ofaa415 |
Ejemplares similares
-
Long-term Safety and Tolerability of Omadacycline for the Treatment of Mycobacterium abscessus Infections
por: Mingora, Christina M, et al.
Publicado: (2023) -
Omadacycline for the treatment of Mycobacterium abscessus infections: Case series and review of the literature
por: Siddiqa, Ayesha, et al.
Publicado: (2023) -
Omadacycline Potentiates Clarithromycin Activity Against Mycobacterium abscessus
por: Bich Hanh, Bui Thi, et al.
Publicado: (2021) -
Omadacycline as a promising new agent for the treatment of infections with Mycobacterium abscessus
por: Bax, Hannelore I, et al.
Publicado: (2019) -
Preliminary, Real-world, Multicenter Experience With Omadacycline for Mycobacterium abscessus Infections
por: Morrisette, Taylor, et al.
Publicado: (2021)